We are live on ! Find out more

Geron

GERN

Market cap $790M

1.23 USD

+0.04

3.36%

At close Updated Oct 15, 4:00 PM EDT

Pre-market

After hours

1.24

+0.01

0.81%

1 day

3.36%

5 days

0.82%

1 month

-6.11%

3 months

-13.38%

6 months

-27.22%

Year to date

-6.82%

1 year

-3.91%

5 years

-12.77%

10 years

-40.87%

About: Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.

Employees: 258

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 21.1%

Neutral 78.9%

Negative 0%

Did Geron Corporation Insiders Breach their Fiduciary Duties to Shareholders?

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

Did Geron Corporation Insiders Breach their Fiduciary Duties to Shareholders?

Geron Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Geron Corporation - GERN

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Geron Corporation (“Geron” or the “Company”) (NasdaqGS: GERN).Throughout 2024, the Company touted the revenue outlook and anticipated growth of its primary product, imetelstat, a telomerase inhibitor that it sells under the brand name, Rytelo, designed to reduce the prolif.

Geron Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Geron Corporation - GERN

Did Geron Corporation Insiders Breach their Fiduciary Duties to Shareholders?

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

Did Geron Corporation Insiders Breach their Fiduciary Duties to Shareholders?

Geron Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Geron Corporation - GERN

NEW YORK and NEW ORLEANS, Sept. 25, 2026 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C.

Geron Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Geron Corporation - GERN

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer, today reported that, effective September 17, 2026, it granted stock options to purchase an aggregate of 821,250 shares of common stock to nine newly hired employees as an inducement material to such employees' acceptance of employment with Geron.

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Geron Eyes High End of 2026 RYTELO Revenue Guidance as Community Adoption Expands

Geron NASDAQ: GERN executives said the company remains on track to generate 2026 RYTELO net revenue of $220 million to $240 million, with Chief Executive Officer Harout Semerjian saying the company now expects results toward the midpoint to high end of that range, or approximately $230 million to $240 million.

Geron Eyes High End of 2026 RYTELO Revenue Guidance as Community Adoption Expands

Geron Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Geron Corporation - GERN

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Geron Corporation (“Geron” or the “Company”) (NasdaqGS: GERN). Throughout 2024, the Company touted the revenue outlook and anticipated growth of its primary product, imetelstat, a telomerase inhibitor that it sells under the brand name, Rytelo, designed to reduce the.

Geron Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Geron Corporation - GERN

Geron Sees RYTELO Revenue Near High End of 2026 Guidance as Community Use Expands

Geron NASDAQ: GERN said it expects full-year net revenue from RYTELO to land in the mid-to-high end of its previously stated range, or approximately $230 million to $240 million, as the company continues to expand use of the telomerase inhibitor in lower-risk myelodysplastic syndromes, or MDS.

Geron Sees RYTELO Revenue Near High End of 2026 Guidance as Community Use Expands

Did Geron Corporation Insiders Breach their Fiduciary Duties to Shareholders?

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

Did Geron Corporation Insiders Breach their Fiduciary Duties to Shareholders?

Kuehn Law Encourages Investors of Geron Corporation to Contact Law Firm

NEW YORK, Sept. 2, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Geron Corporation (NASDAQ: GERN) breached their fiduciary duties to shareholders.

Kuehn Law Encourages Investors of Geron Corporation to Contact Law Firm

See News Rankings

Price charts implemented using Lightweight Charts™